List of Figures:
Figure 1. Research Method Flow Chart 11
Figure 2. Breakdown of Primary Research 13
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation 15
Figure 4. North America Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2021-2030 17
Figure 5. North America Pharmaceutical CRO Market, 2019-2030, $ bn 20
Figure 6. Impact of COVID-19 on Business 23
Figure 7. Primary Drivers and Impact Factors of North America Pharmaceutical CRO Market 25
Figure 8. Leading Causes of Death in the World, 2019-2020, million 30
Figure 9. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million 31
Figure 10. World Population 65 and Over, % of Total Population, 1950-2060 31
Figure 11. Primary Restraints and Impact Factors of North America Pharmaceutical CRO Market 33
Figure 12. Investment Opportunity Analysis 37
Figure 13. Porter’s Fiver Forces Analysis of North America Pharmaceutical CRO Market 40
Figure 14. Breakdown of North America Pharmaceutical CRO Market by Service, 2019-2030, % of Sales Revenue 45
Figure 15. North America Addressable Market Cap in 2022-2030 by Service, Value ($ bn) and Share (%) 45
Figure 16. North America Pharmaceutical CRO Market: CRO for Pre-clinical Development, 2019-2030, $ bn 46
Figure 17. North America Pharmaceutical CRO Market: CRO for Phase I Trials, 2019-2030, $ bn 47
Figure 18. North America Pharmaceutical CRO Market: CRO for Phase II Trials, 2019-2030, $ bn 48
Figure 19. North America Pharmaceutical CRO Market: CRO for Phase III Trials, 2019-2030, $ bn 49
Figure 20. North America Pharmaceutical CRO Market: CRO for Phase IV Trials, 2019-2030, $ bn 50
Figure 21. North America Pharmaceutical CRO Market: Laboratory Services, 2019-2030, $ bn 51
Figure 22. North America Pharmaceutical CRO Market: Consulting Services, 2019-2030, $ bn 52
Figure 23. North America Pharmaceutical CRO Market: Data Management Services, 2019-2030, $ bn 53
Figure 24. Breakdown of North America Pharmaceutical CRO Market by Therapeutic Application, 2019-2030, % of Sales Revenue 55
Figure 25. North America Addressable Market Cap in 2022-2030 by Therapeutic Application, Value ($ bn) and Share (%) 55
Figure 26. North America Pharmaceutical CRO Market: Infectious Diseases, 2019-2030, $ bn 56
Figure 27. North America Pharmaceutical CRO Market: Oncology, 2019-2030, $ bn 57
Figure 28. North America Pharmaceutical CRO Market: Metabolic Disorders, 2019-2030, $ bn 58
Figure 29. North America Pharmaceutical CRO Market: Cardiovascular Disorders, 2019-2030, $ bn 59
Figure 30. North America Pharmaceutical CRO Market: Central Nervous System, 2019-2030, $ bn 60
Figure 31. North America Pharmaceutical CRO Market: Respiratory Disorders, 2019-2030, $ bn 61
Figure 32. North America Pharmaceutical CRO Market: Gastrointestinal Disorders, 2019-2030, $ bn 62
Figure 33. North America Pharmaceutical CRO Market: Other Therapeutic Applications, 2019-2030, $ bn 63
Figure 34. Breakdown of North America Pharmaceutical CRO Market by End User, 2019-2030, % of Revenue 65
Figure 35. North America Addressable Market Cap in 2022-2030 by End User, Value ($ bn) and Share (%) 65
Figure 36. North America Pharmaceutical CRO Market: Pharmaceutical & Biopharmaceutical Companies, 2019-2030, $ bn 66
Figure 37. North America Pharmaceutical CRO Market: Medical Device Companies, 2019-2030, $ bn 67
Figure 38. North America Pharmaceutical CRO Market: Academic Institutes, 2019-2030, $ bn 68
Figure 39. Breakdown of North America Pharmaceutical CRO Market by Country, 2021 and 2030, % of Revenue 70
Figure 40. Contribution to North America 2022-2030 Cumulative Revenue by Country, Value ($ bn) and Share (%) 71
Figure 41. U.S. Pharmaceutical CRO Market, 2019-2030, $ bn 73
Figure 42. Canada Pharmaceutical CRO Market, 2019-2030, $ bn 75
Figure 43. Pharmaceutical CRO Market in Mexico, 2015-2030, $ bn 77
Figure 44. Growth Stage of North America Pharmaceutical CRO Industry over the Forecast Period 79
North America pharmaceutical contract research organization (CRO) market is projected to grow by 9.0% annually in the forecast period and reach $37.61 billion by 2030, driven by the increasing incidence of disease, rising healthcare expenditures, increasing dependence on contract research organizations due to improved efficiency and productivity. Highlighted with 59 tables and 44 figures, this 132-page report “North America Pharmaceutical Contract Research Organization (CRO) Market 2021-2030 by Service, Therapeutic Application, End User, and Country: Trend Forecast and Growth Opportunity” is based on comprehensive research of the entire North America pharmaceutical contract research organization (CRO) market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2019-2021 and provides forecast from 2022 till 2030 with 2021 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify North America pharmaceutical contract research organization (CRO) market in every aspect of the classification from perspectives of Service, Therapeutic Application, End User, and Country. Based on Service, the North America market is segmented into the following sub-markets with annual revenue ($ bn) for 2021-2030 included in each section. • CRO for Pre-clinical Development • CRO for Phase I Trials • CRO for Phase II Trials • CRO for Phase III Trials • CRO for Phase IV Trials • Laboratory Services • Consulting Services • Data Management Services Based on Therapeutic Application, the North America market is segmented into the following sub-markets with annual revenue ($ bn) for 2021-2030 included in each section. • Infectious Diseases • Oncology • Metabolic Disorders • Cardiovascular Disorders • Central Nervous System • Respiratory Disorders • Gastrointestinal Disorders • Other Therapeutic Applications By End User, the North America market is segmented into the following sub-markets with annual revenue ($ bn) for 2021-2030 included in each section. • Pharmaceutical & Biopharmaceutical Companies • Medical Device Companies • Academic Institutes Geographically, the following national/local markets are fully investigated: • U.S. • Canada • Mexico For each key country, detailed analysis and data for annual revenue ($ bn) are available for 2021-2030. The breakdown of key national markets by Service, Therapeutic Application, and End User over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Selected Key Players: Charles River Laboratories CMIC Co. Ltd Covance Inc. Hangzhou Tigermed Consulting Co., Ltd. ICON Plc IQVIA Holdings Inc. LSK Global Pharma Service Co., Ltd. Novotech Pty Ltd PAREXEL International Corporation Pharmaceutical Product Development LLC (PPD) PRA Health Sciences Inc. Quanticate Ltd Samsung Bioepis Co., Ltd. SGS SA (SGS Life Sciences) Syneos Health Inc. WuXi AppTec Inc. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Read More